Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Hilton Lac-Leamy

Nov 14, 2024 7:30 AM - Nov 15, 2024 4:10 PM

3 Boulevard du Casino, Gatineau, QC J8Y 6X4, Canada

Canada Annual Meeting

The Canada Annual Meeting offers three tracks, Regulatory, Clinical, Safety and Pharmacovigilance!

Time to Register!

DAYS

HOURS

MINUTES

SECONDS

Overview

Meeting: November 14-15 | In-Person

Short Course: November 5 | Virtual

The DIA Canada Annual Meeting will provide an in-depth exploration of the current pharmaceutical, medical device, and diagnostic landscapes in Canada, emphasizing Canada’s pivotal role in global healthcare product development. Offering three specialized tracks on Regulatory, Clinical, and Safety and Pharmacovigilance, the meeting will cover topics spanning from Health Canada’s latest regulatory initiatives, international collaboration, and innovative clinical practices to approaches that harness AI in drug safety and increase representation from equity-denied groups.

Attendees will have the opportunity to engage with leaders and experts from academia, regulatory bodies, and the pharmaceutical and medical device industries by gaining insights into best practices, lessons learned, and strategies to address the challenges facing stakeholders in Canada.

Participant Testimonials

What a wonderful event to get up to speed on the latest regulatory and industry developments for drugs and devices, directly from experts and leaders in the field, that includes a number of opportunities to network and get to know speakers and presenters. – Kelly McClellan - Federal Government Canada

Excellent meeting, the presenters from industry and Health Canada were knowledgeable and fully engaged. – Patricia Smith – Otsuka

The quality of the presentations was high and all information discussed was relevant for our job. The ambience was favourable for discussions and great interaction among participants. – Celline Brasil – Health Canada

Featured

Want to learn more about Canada Annual Meeting? You've come to the right site!

Continuing Education

Exhibits

Highlights & Features

Check out the great content lined up for the Regulatory, Clinical, Safety and Pharmacovigilance tracks at Canada Annual Meeting.

Program Welcome Video

Who should attend?

  • Meeting Designed For:

    Join professionals interested in a comprehensive overview of the current biopharma pharmaceutical, medical device, and/or diagnostics landscape in Canada:

    • Pharmacovigilance and Drug Safety
    • Risk Management
    • Clinical Research, Management, and Operations
    • Regulatory Affairs and Operations
    • Medical Affairs and Scientific Communication
    • Quality Assurance
    • Life Sciences R&D
    • Project Management
    • Real-World Data and Real-World Evidence
    • Data Management

Learning objectives

  • Upon completion, learners should be able to:

    • Identify Health Canada's Precision Regulating Initiatives and amendments to the Food and Drugs Act to ensure precise regulatory solutions
    • Discuss Health Canada's international collaboration initiatives and their impact on regulatory processes and clinical trials
    • Determine the unique advantages and challenges of conducting clinical trials in Canada and how it positions itself as a global leader
    • Develop strategies to enhance equity, diversity, inclusion, and accessibility in clinical trials, focusing on underrepresented groups
    • Evaluate the latest developments in pharmacovigilance, including Health Canada's guidance on adverse drug reaction reporting and post-market surveillance
    • Examine the role of artificial intelligence in regulatory processes, clinical development, and pharmacovigilance, and understand the implications for the industry
    • Evaluate pathways for drug development and patient access in the rare diseases sector, focusing on regulatory strategies and collaboration opportunities
    • Identify decentralized clinical trials, electronic patient medication information, and innovative approaches in clinical trial operations
    • Discuss the importance of transparency in regulatory submissions and the role of data anonymization in protecting personal and confidential business information

Short Course or Primer

To keep you at the forefront.

Nov 05, 2024

Short Course:

Best Practices for Clinical Trial Applications in Canada

Program Committee

  • Stephanie  Anderson, MS
    Stephanie Anderson, MS Associate Director, Regulatory Affairs
    Intrinsik Corp., Canada
  • Rebecca  Barnes, MS
    Rebecca Barnes, MS Executive Director
    Network of Networks (N2), Canada
  • Vatche  Bartekian, MSc
    Vatche Bartekian, MSc President
    Vantage BioTrials, Canada
  • Katalin  Bertenyi, MSc
    Katalin Bertenyi, MSc Manager, Centre for Blood, Blood Products and Biotherapeutics
    Health Canada, Canada
  • Louise  Blythe, MS, MSc
    Louise Blythe, MS, MSc VP & Head, Regulatory Affairs
    Bayer Inc. Canada, Canada
  • Melanie  Cote, MS
    Melanie Cote, MS Senior Manager, Global Regulatory Affairs
    Otsuka Canada Pharmaceutical Inc., Canada
  • My  Dang, MBA
    My Dang, MBA Director/Consultant, Regulatory Affairs
    Cencora, Canada
  • Tharany  Ganesh, MSc
    Tharany Ganesh, MSc Head, Regulatory Affairs
    AstraZeneca Canada Inc., Canada
  • Marie-France  Goyer, MSc
    Marie-France Goyer, MSc Director, Clinical Operations
    Abcellera, Canada
  • Daniel  Greco, PharmD, RPh
    Daniel Greco, PharmD, RPh Associate Director of Patient Safety
    Bristol-Myers Squibb Company, Canada
  • Brenda  Gryfe, MSc
    Brenda Gryfe, MSc Regulatory Consultant
    Flying Moose Technologies , Canada
  • Oxana  Iliach, PhD
    Oxana Iliach, PhD Senior Director Regulatory Strategy
    Certara, Canada
  • Nadiya  Jirova, MSc
    Nadiya Jirova, MSc Manager, Bureau of Biologics, Radiopharmaceuticals and Self-Care Products
    Health Canada, Canada
  • Mei  Lam, BSN, RN
    Mei Lam, BSN, RN Canada PV Manager/Safety Regional Country Contact
    Haleon, Canada
  • Randy  Levitt, PhD
    Randy Levitt, PhD Director, Pharmacovigilance and Medical Affairs
    Paladin Pharma Inc., Canada
  • Amber  McLeod, PhD
    Amber McLeod, PhD Immunology, Virology, and Specialty Head, Regulatory Affairs
    Abbvie Corporation, Canada
  • Nadia  Mian, MS
    Nadia Mian, MS Senior Manager, Pharmacovigilance
    Ipsen Biopharmaceuticals Canada Inc., Canada
  • Myriam  Salem, MSc
    Myriam Salem, MSc Good Pharmacovigilance Practices National Coordinator
    Health Canada, Canada
  • Marcia  Sam
    Marcia Sam Senior Manager, Regulatory Affairs
    Regeneron Canada Company, Canada
  • Vanessa  Zapata
    Vanessa Zapata Associate Director, Regional Pharmacovigilance Officer
    Merck Canada Inc., Canada
  • Representative Invited
    Representative Invited DIA, United States

Digital Learning Catalog

DIA Learning: eLearning Soultions
Download

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.